Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012:2012:423520.
doi: 10.1155/2012/423520. Epub 2012 Jun 13.

Is there a role for postmastectomy radiation therapy in ductal carcinoma in situ?

Affiliations

Is there a role for postmastectomy radiation therapy in ductal carcinoma in situ?

Manjeet Chadha et al. Int J Surg Oncol. 2012.

Abstract

Background. DCIS treated by mastectomy ensures high local control rates. There is limited data on risk for relapse and lack of clear indication for adjuvant radiation therapy (RT). We report a retrospective review on a population of DCIS patients treated with mastectomy. The objective was to identify the overall incidence of relapse, risk factors for local recurrence, and accordingly for whom adjuvant postmastectomy RT may be considered. Methods. This is an IRB-approved retrospective study on a prospective breast cancer database. From 1997 to 2007, we identified 969 patients with diagnoses of DCIS, among them 211 breasts in 207 patients were treated with mastectomy and comprise the study group. Results. With a median followup of 55 months (4.6 years) the 10-year relapse-free survival is 97%. Two of 211 breasts (0.9%) treated with mastectomy developed a local-regional recurrence. Both the relapses were among patients defined as having <1 mm final mastectomy margin. Conclusions. The rare local relapse after mastectomy limits our ability to reliably identify risk factors for relapse. The consideration for postmastectomy RT should be based on an individualized risk evaluating surgical technique used, presence of BRCA mutation, grade and extent of tumor, and proximity of lesion to the margin of resection.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Local-Regional relapse-free survival curve for total cohort (N = 211).

Similar articles

Cited by

References

    1. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics 2011. CA Cancer Journal. 2011;61(4):212–236. - PubMed
    1. Smith GL, Smith BD, Haffty BG. Rationalization and regionalization of treatment for ductal carcinoma in situ of the breast. International Journal of Radiation Oncology Biology Physics. 2006;65(5):1397–1403. - PubMed
    1. Ernster VL, Barclay J, Kerlikowske K, Grady D, Henderson IC. Incidence of and treatment for ductal carcinoma in situ of the breast. Journal of the American Medical Association. 1996;275(12):913–918. - PubMed
    1. Burstein HJ, Polyak K, Wong JS, Lester SC, Kaelin CM. Ductal carcinoma in situ of the breast. New England Journal of Medicine. 2004;350(14):1430–1441. - PubMed
    1. Kuerer HM, Albarracin CT, Yang WT, et al. Ductal carcinoma in situ: state of the science and roadmap to advance the field. Journal of Clinical Oncology. 2009;27(2):279–288. - PubMed

LinkOut - more resources